Table 2. Seroprevalence of SARS-COV-2 antibodies by age, sex, and medical history in 2 consecutive population-based surveys during second wave of COVID-19, Yaoundé, Cameroon, 2021* .
| Characteristic | Participants, survey 1, January 27–February 6 |
Participants, survey 2, April 24–May 19 |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Total no. | No. (%) positive | % Positive (95% CI) | p value | Total no. | No. (%) positive | % Positive (95% CI) | p value | ||
| Age group, y | 0.002 | <0.001 | |||||||
| 0–19 | 236 | 31 | 13.1 (9.3–18.3) | 468 | 200 | 42.7 (38.3–47.3) | |||
| 20–39 | 276 | 71 | 25.7 (20.8–31.4) | 440 | 263 | 59.8 (55.0–64.4) | |||
|
>40 |
210 |
48 |
22.9 (17.5–29.2) |
|
|
320 |
201 |
62.8 (57.3–68.0) |
|
| Sex | 0.773 | 0.942 | |||||||
| F | 423 | 89 | 18.5 (14.8–22.9) | 718 | 392 | 51.0 (47.1–54.8) | |||
| M |
299 |
61 |
19.0 (14.8–24.1) |
|
|
510 |
272 |
51.6 (47.0–56.1) |
|
| No. symptoms | 0.688 | 0.288 | |||||||
| 0 | 271 | 70 | 22.5 (17.8–28.0) | 776 | 424 | 51.8 (48.1–55.5) | |||
| 1–2 | 157 | 26 | 12.8 (7.5–21.0) | 257 | 129 | 47.8 (41.6–54.0) | |||
| 3–5 | 134 | 27 | 22.5 (13.5–35.2) | 167 | 92 | 53.9 (45.6–61.9) | |||
| >5 |
68 |
17 |
18.4 (8.4–35.9) |
|
|
28 |
19 |
57.5 (39.0–75.7) |
|
| Hospitalization | 0.150 | 0.487 | |||||||
| Yes | 28 | 6 | 10.7 (4.4–23.6) | 12 | 8 | 51.0 (17.3–83.9) | |||
| No |
329 |
64 |
18.0 (12.8–24.7) |
|
|
445 |
229 |
50.1 (45.1–55.2) |
|
| Total | 722 | 150 | 18.6 (15.7–21.7) | 1 228 | 664 | 51.3 (48.3–54.2) | |||
*Overall seroprevalence estimate was age-standardized, based on available demographic data (12).